539 related articles for article (PubMed ID: 18543035)
1. Review of fecal biomarkers in inflammatory bowel disease.
Sutherland AD; Gearry RB; Frizelle FA
Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
[TBL] [Abstract][Full Text] [Related]
2. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.
Lundberg JO; Hellström PM; Fagerhol MK; Weitzberg E; Roseth AG
Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):96-102. PubMed ID: 16265127
[TBL] [Abstract][Full Text] [Related]
3. Fecal markers: calprotectin and lactoferrin.
Abraham BP; Kane S
Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
Caccaro R; D'Incá R; Sturniolo GC
Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
6. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
7. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
Schröder O; Naumann M; Shastri Y; Povse N; Stein J
Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease.
Joishy M; Davies I; Ahmed M; Wassel J; Davies K; Sayers A; Jenkins H
J Pediatr Gastroenterol Nutr; 2009 Jan; 48(1):48-54. PubMed ID: 19172123
[TBL] [Abstract][Full Text] [Related]
10. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests].
Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M
Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
12. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
Gisbert JP; McNicholl AG
Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
[TBL] [Abstract][Full Text] [Related]
13. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
14. [Measurement of calprotectin in faeces].
Jahnsen J; Røseth AG; Aadland E
Tidsskr Nor Laegeforen; 2009 Apr; 129(8):743-5. PubMed ID: 19373299
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of fecal calprotectin concentration as inflammatory marker in inflammatory bowel diseases in children--preliminary report].
Krzesiek E; Iwańczak B
Pol Merkur Lekarski; 2010 Oct; 29(172):241-6. PubMed ID: 21207640
[TBL] [Abstract][Full Text] [Related]
16. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
Grad C; David L; Portincasa P; Dumitraşcu DL
Rom J Intern Med; 2012; 50(1):3-6. PubMed ID: 22788087
[TBL] [Abstract][Full Text] [Related]
18. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
[TBL] [Abstract][Full Text] [Related]
19. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
Kolho KL; Raivio T; Lindahl H; Savilahti E
Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
